16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors
Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach
https://www.globenewswire.com/news-release/2024/09/23/2951246/0/en/Skye-Bioscience-Comments-on-Monlunabant-Phase-2-Top-line-Data-and-Reiterates-Confidence-in-Nimacimab-Clinical-Development-Plan.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.